Amylyx Pharmaceuticals Inc (AMLX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Amylyx Pharmaceuticals Inc

Healthcare (1096)

617-682-0917

55 CAMBRIDGE PARKWAY, CAMBRIDGE

Prossima data di guadagno

Ultimi documenti SEC

AMLX's Discussions on Twitter

Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AMLX Amylyx Pharmaceuticals Inc	17.77	1.98B	-665.00K	-150.11M	-124.53M	-1.5071
TAK Takeda Pharmaceutical Co Adr	16.56	52.88B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.76	42.98B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	32.95	38.37B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.56	31.68B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.06	23.22B	3.17B	1.29B	1.01B	27.09

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-03	Iniziato	Stifel	Buy
2025-07-10	Ripresa	Goldman	Buy
2025-06-24	Iniziato	Guggenheim	Buy
2025-06-17	Iniziato	Citigroup	Buy
2025-05-30	Iniziato	TD Cowen	Buy
2025-04-07	Aggiornamento	Mizuho	Neutral → Outperform
2024-11-18	Aggiornamento	Robert W. Baird	Neutral → Outperform
2024-10-23	Aggiornamento	BofA Securities	Neutral → Buy
2024-03-18	Downgrade	Mizuho	Buy → Neutral
2024-03-11	Downgrade	Leerink Partners	Outperform → Market Perform
2024-03-11	Downgrade	Robert W. Baird	Outperform → Neutral
2024-03-08	Downgrade	Evercore ISI	Outperform → In-line
2024-03-08	Downgrade	Goldman	Buy → Neutral
2024-01-03	Iniziato	Robert W. Baird	Outperform
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-07-24	Aggiornamento	Goldman	Neutral → Buy
2023-03-31	Iniziato	Mizuho	Buy
2023-01-05	Iniziato	BofA Securities	Buy
2022-05-25	Iniziato	Citigroup	Buy
2022-04-01	Downgrade	Goldman	Buy → Neutral

Mostra tutto

Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie

Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari

Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie

Amylyx Pharmaceuticals (AMLX) M&A Announcement Summary - Quartr

Amylyx Pharmaceuticals (AMLX) Proxy filing Summary - Quartr

Form 144 Amylyx Pharmaceuticals For: 9 July By Investing.com - Investing.com India

[144] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - aol.com

Amylyx Pharmaceuticals (AMLX) Q3 2024 earnings summary - Quartr

Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight - Yahoo Finance

AMLXAmylyx Pharmaceuticals Inc Latest SEC Filings - Finviz

Companies Like Amylyx Pharmaceuticals (NASDAQ:AMLX) Are In A Position To Invest In Growth - Moomoo

Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? - Insider Monkey

Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell 3000E Index - marketscreener.com

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index - marketscreener.com

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Value Benchmark - marketscreener.com

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark - marketscreener.com

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com

Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gew - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Amylyx advancing ALS treatment in trial after early safety data is positive - ALS News Today

Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView

Price to sales forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView

Enterprise value to EBITDA forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView

Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Amylyx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMLX) - TradingView

AMLX Forecast — Price Target — Prediction for 2027 - TradingView

Amylyx Pharmaceuticals stock hits 52-week high at $18.65 By Investing.com - Investing.com South Africa

AMLX Maintained by Guggenheim -- Price Target Raised to $40 - GuruFocus

Guggenheim raises Amylyx stock price target on PBH drug outlook By Investing.com - Investing.com South Africa

Guggenheim raises Amylyx stock price target on PBH drug outlook - Investing.com UK

Amylyx Pharmaceuticals stock hits 52-week high at $18.65 - Investing.com

Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $40 - Moomoo

H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $34 - Moomoo

Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 - BioSpace

Amylyx presents early safety data for ALS drug candidate AMX0114 By Investing.com - Investing.com Nigeria

Amylyx presents early safety data for ALS drug candidate AMX0114 - Investing.com

Amylyx says ALS drug AMX0114 showed no serious safety issues - Stock Titan

Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Firestone Karen - Moomoo

Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MILNE GEORGE M JR - Moomoo

Goldman Sachs Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $23 - Moomoo

Amylyx Pharmaceuticals Inc (AMLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Amylyx Pharmaceuticals Inc (AMLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence - TradingKey

Amylyx Pharmaceuticals Inc (AMLX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Amylyx Pharmaceuticals Inc (AMLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a AMLX